Enfermedad respiratoria exacerbada por antiinflamatorios no esteroideos: conocimientos y tendencias actuales

Eglis Ceballos Rodríguez, Juan Miguel Báez López, Iglermys Figueroa García, Ilonka María Estruch Fajardo, Armando Ginard Cabanas

Texto completo:

PDF

Resumen

Introducción: La enfermedad respiratoria exacerbada por antiinflamatorios no esteroideos, es una enfermedad crónica y resistente al tratamiento, caracterizada por la presencia de rinosinusitis eosinofílica, poliposis nasal, asma bronquial e hipersensibilidad a los fármacos antiinflamatorios no esteroideos.

Objetivo: Profundizar, con conocimientos actualizados, en el diagnóstico y tratamiento de esta enfermedad.

Métodos: Revisión exhaustiva de la evidencia actual, basado en publicaciones recientes que abordan el tema, realizadas durante el período de noviembre/2019 a abril/2020, se utilizaron motores de búsquedas a través de bases de datos científicas como PubMed, SciElo, ReserchGate, Scopus, ScienceDirect, y Google académico, y fueron consultadas varias fuentes como revistas y libros electrónicos publicados en español e inglés.

Conclusiones: A pesar de algunos avances en la comprensión de la fisiopatología, la enfermedad respiratoria exacerbada por antiinflamatorios no esteroideos sigue siendo un desafío diagnóstico y terapéutico. El diagnóstico oportuno permitirá el tratamiento multidisciplinar adecuado y evitará serias complicaciones. La desensibilización a la aspirina es una opción terapéutica eficaz y segura para un óptimo control de la enfermedad.

Palabras clave: Antiinflamatorios no esteroideos; fisiopatología; hipersensibilidad; rinosinusitis eosinofílica.

Palabras clave

Antiinflamatorios no esteroideos; fisiopatología; hipersensibilidad; rinosinusitis eosinofílica.

Referencias

Han J, Tan Y, Ann A, Hsu L. Nonsteroidal anti-inflammatory drug (NSAID) exacerbated respiratory disease phenotype: Topical NSAID and asthma control: A possible oversight link. Resp Med 2016 [acceso: 03/03/2020]; 118:1-3. Available in: https://doi.org/10.1016/j.rmed.2016.07.004Get rights and content

Tanya M. Laidlaw TM, Cahill KN. Current Knowledge and Management of Hypersensitivity to Aspirin and NSAIDs. J Allergy Clin Immunol Pract 2017 [acceso: 20/02/2020]; 5(3):537-45 Available in: https://www.sciencedirect.com/science/article/abs/pii/S2213219816305591

Rodríguez JC, Jiménez F, Moreno-Paz J, Terán LM, Guaní-Guerra E. Aspirin exacerbated respiratory disease: Current topics and trends. Resp Med 2018 [acceso: 31/01/2020]; 135:62-75 Available in: https://www.sciencedirect.com/science/article/pii/S0954611118300039

San Nicoló M, Högerle C, Gellrich D, Eder K, Pfrogner E, Gröger M. The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data. Eur Arch Otorhinolaryngol 2020 [acceso: 13/01/2020]; 277(2):445-52 Available in: https://europepmc.org/article/med/31655881

Agúndez JAG, Selinski S, Corsini E, Golka K, García-Martín E. Biomarkers in drug hypersensitivity. Front Pharmacol 2017 [acceso: 21/03/2020]; 8:348 Disponible en: https://doi.org/10.3389/fphar.2017.00348

Cavkaytar O. Characteristics of NSAID‐induced hypersensitivity reactions in childhood. Ped Allergy Immunol 2018 [acceso: 20/02/2020]; 30(1) Available in: https://doi.org/10.1111/pai.12980

Laidlaw TM, Israel E. Aspirin-exacerbated respiratory disease. UpToDate 2020 [acceso: 1/04/2020] Available in: https://www.uptodate.com/contents/aspirin-exacerbated-respiratory-disease

Jang DW, Comer BT, Lachanas VA, Kountakis SE. Aspirin sensitivity does not compromise quality-of-life outcomes in patients with Samter's triad. Laryngosc 2014 [acceso: 12/02/2020]; 124(1):34-7. Available in: https://doi.org/10.1002/lary.24220

Stevens WW, Schleimer RP. Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis. Immunol Allergy Clin N Am 2016 [acceso: 15/02/2020]; 36(4): 669-80 Available in: http://dx.doi.org/10.1016/j.iac.2016.06.004

Arias Arcos MB. EREA: La enfermedad respiratoria exacerbada por aspirina. Rev Patol Resp 2019 [acceso: 12/0472020]; 22(2): 59-65. Disponible en: https://pesquisa.bvsalud.org/portal/resource/pt/ibc-FGT-2141

Méndez Sánchez A, Gutiérrez Martínez JR, Coca Pelaz A, Vázquez Piñera MA. Enfermedad respiratoria relacionada con aspirina tratada con mepolizumab en un paciente pediátrico. Arch Bronconeumol 2017 [acceso: 11/03/2020]; 55(1):55-7 Available in: https://doi.org/10.1016/j.arbres.2018.04.012

Calderón JC, Dávila F, Mantilla R, Chérrez A, Calero E, Cabrera D, et al. Conocimiento y actitudes en médicos ecuatorianos sobre enfermedades respiratorias exacerbadas por aspirina. Rev. alerg. Méx 2017 [acceso: 02/04/2020]; 64(1) Disponible en: http://dx.doi.org/10.29262/ram.v64i1.219

Ginard Cabanas A, Ceballos Rodríguez E, Báez López JM, Figueroa García I, Estruch Fajardo I. Caracterización de pacientes con enfermedad respiratoria exacerbada por el uso de la aspirina y otros antiinflamatorios no esteroideos. Rev Act Med 2019; 20(1) Disponible en: http://www.revactamedica.sld.cu/index.php/act/issue/view/1

Yeung WY, Park HS. Update on the Management of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity. Yonsei Med J 2020 [acceso: 20/01/2020]; 61(1):4-14 Available in: https://doi.org/10.3349/ymj.2020.61.1.4

Duarte de Prato AA. Reacciones de hipersensibilidad a los antinflamatorios no esteroideos. Tesis doctoral 2010 [acceso: 14/02/2020]. Disponible en: https://www.tesisenred.net/handle/10803/10742#page=1

Doña I, Pérez‐Sánchez N, Eguiluz‐Gracia I, Muñoz‐Cano R, Bartra J, Torres MJ, et al. Progress in understanding hypersensitivity reactions to nonsteroidal anti‐inflammatory drugs. J Allergy 2020 [acceso: 03/03/2020]; 75(3):561-75. Available in: https://doi.org/10.1111/all.14032

White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. N Engl J Med 2018 [acceso: 03/03/2020]; 379: 1060-70. Available in: https://doi.org/10.1056/NEJMra1712125

Wongsa Ch, Sompornrattanaphan M, Tantilipikorn P, Thongngarm T. Clinical characteristics and aspirin desensitization in Thai patients with a suggestive history of NSAID-exacerbated respiratory disease. Asian Pac J Allergy Immunol 2019 [acceso: 28/02/2020] Available in: https://doi.org/10.12932/ap-150619-0583

Laidlaw T.M., Levy, J.M. NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets. Curr Allergy Asth Rep 2020 [acceso: 16/02/2020]; 20(4):10 Available in: https://doi.org/10.1007/s11882-020-00905-9)

- Arikoglu T, Aslan G, Yildirim D , BirgulBatmaz S , Kuyucu S. Discrepancies in the diagnosis and classification of nonsteroidal anti-inflammatory drug hypersensitivity reactions in children. Allergol Intern 2017 [acceso: 25/01/2020]; 66(3):418-24 Available in: https://doi.org/10.1016/j.alit.2016.10.004)

Izquierdo-Domínguez A, Campo P, Torres MJ, Dordal MT. Statement of the spanish society of allergology and clinical immunology on provocation tests with aspirin/nonsteroidal anti-inflammatory drugs. J Invest Allergol Clin Immunol 2020 [acceso: 31/01/2020]; 30(1):1-13 Available in: https://doi.org/10.18176/jiaci.0449

Doña I, Barrionuevo E, Salas M, Laguna JJ, Agondez J, García-Martín E, et al. NSAIDs-hypersensitivity often induces a blended reaction pattern involving multiple organs. Sci Rep 2018 [acceso: 12/02/2020]; 8,16710 Available in: https://doi.org/10.1038/s41598-018-34668-1

Ayuso P, Plaza-Serón MC, López NB, Doña I, Campo P, Canto G, et al. Genetic variants in arachidonic acid pathway genes associated with NSAID-exacerbated respiratory disease. Pharmacogen 2015 [acceso: 13/02/2020]; 16(8) Available in: https://doi.org/10.2217/pgs.15.43)

Calvo Campoverde K, Giner-Muñoz MT, Martínez Valdez L, Rojas Volquez M, Lozano Blasco J, Machinena A, et al. Reacciones de hipersensibilidad a antiinflamatorios no esteroideos y su tolerancia a fármacos alternativos. An Pediatr (Barc) 2016 [acceso: 21 mar 2020]; 84(3):148-53. Available in: https://doi.org/10.1016/j.anpedi.2015.05.004

Plaza Seron MC. Reacciones de hipersensibilidad por intolerancia cruzada a antiinflamatorios no esteroideos: relacion fenotipo-genotipo. Tesis doctoral 2016 [acceso: 14/03/2020] Disponible en: https://riuma.uma.es/xmlui/bitstream/handle/10630/13245/TD_PLAZA_SERON_Maria_del_Carmen.pdf?sequence=1&isAllowed=y

Rodríguez-Jiménez JC, Moreno-Paz FJ, Terán LM, Guaní-Guerra E. Aspirin exacerbated respiratory disease: Current topics and trends. Resp Med 2018 [acceso: 26/04/2020]; 135: 62-75. Available in: https://doi.org/10.1016/j.rmed.2018.01.002

Sarraquigne MP, Mariño AI, Saranz R, Colella M, López K, Bovina Martijena MP et al. Alergia e intolerancia a antiinflamatorios no esteroideos en pediatría. Arch Arg Pediatr 2020 [acceso: 29/04/2020]; 118(1):S1-S11 Available in: http://dx.doi.org/10.5546/aap.2020.S1

Cortellini G, Caruso C, Romano A. Aspirin challenge and desensitization: how, when and why. Curr Opin Allergy Clin Immunol 2017 [acceso: 02/05/2020];17(4):247-54. Available in: https://doi.org/10.1097/ACI.0000000000000374

Lee EY, Teitelbaum D, Chiam M, Vadas P. Characterization of Patients with Ibuprofen Hypersensitivity. Int Arch Allergy Immunol 2019 [acceso: 28/04/2020]; 178(2): 177-81 Available in: https://doi.org/10.1159/000494388

Rivera Reigada ML. Estudio farmacogenético de reacciones de hipersensibilidad a antibióticos beta-lactámicos y a antiinflamatorios no esteroideos. Tesis doctoral 2015. [acceso: 20/02/2020]. Disponible en: https://gredos.usal.es/bitstream/handle/10366/128266/DCBD_RiveraReigadaML_Estudiofarmacogen%E9tico.pdf;jsessionid=3F5C640F055E90EF6D804B9450697CC6?sequence=1

Pham DL, Kim JH, Trinh TH, Park HS. What we know about nonsteroidal anti-inflammatory drug hypersensitivity. Korean J Intern Med 2016 [acceso: 11 mar 2020]; 31(3): 417-32. Available in: https://doi.org/10.3904/kjim.2016.085

Fuertes Ferre G, Cruz Ferrer GM, Calvo Cebollero I. Desensibilización al ácido acetil salicílico en la nueva era del intervencionismo coronario percutáneo. Med Clin (Barc) 2015 [acceso: 02/03/2020];145(6):253-7 Disponible en: https://kundoc.com/pdf-desensibilizacion-al-acido-acetil-salicilico-en-la-nueva-era-del-intervencionism.html

Ponvert C. Les réactions d’hypersensibilité aux antalgiques non opiacés, antipyrétiques et anti-inflammatoires non stéroïdiens. Rev Fr Allergol 2020 [acceso: 19/02/2020]. Available in: https://doi.org/10.1016/j.reval.2020.01.003

Bobolea I, del Pozo V, Sanz V, Cabañas R, Fiandord A, Alfonso-Carrilloe C, et al. Aspirin desensitization in aspirin-exacerbated respiratory disease: New insights into the molecular mechanisms. Resp Med 2018 [acceso: 03/03/2020]; 143:39-41. Available in: https://doi.org/10.1016/j.rmed.2018.08.009

Solomon DH. Overview of COX-2 selective NSAIDs. UpToDate 2020 [acceso: 11/05/2020]. Available in: https://www.uptodate.com/contents/overview-of-cox-2-selective-nsaids

Lee K., Lee SH., Kim TH. The Biology of Prostaglandins and Their Role as a Target for Allergic Airway Disease Therapy. Int J Mol Sci 2020 [acceso: 05/04/2020]; 21(5), [1851]. Available in: https://doi.org/10.3390/ijms21051851)

Holguín-Gómez L, Vásquez-Ochoa LA, Cardona R. Angioedema. Rev Alerg Mex 2016 [acceso: 15/01/2020];63(4):373-84. Disponible en: http://revistaalergia.mx/ojs/index.php/ram/article/viewFile/220/362

Simon RA. NSAIDs (including aspirin): Allergic and pseudoallergic reactions. UpToDate 2018 [acceso: 12/03/2020] Available in: https://www.uptodate.com/contents/nsaids-including-aspirin-allergic-and-pseudoallergic-reactions

Laidlaw TM. Pathogenesis of NSAID-induced reactions in aspirin-exacerbated respiratory disease. World J Otorhinolaryngol - H N Surg 2018 [acceso: 05/04/2020]; 4(3):162-8. Available in: https://doi.org/10.1016/j.wjorl.2018.08.001

Taniguchi M, Mitsui Ch, Hayashi H, Ono E, Kajiwara K, Mita H, et al. Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD. Allergol Int 2019 [acceso: 09/02/2020]; 68(3):289-95. Available in: https://doi.org/10.1016/j.alit.2019.05.001

Solomon DH. Nonselective NSAIDs: Overview of adverse effects. UpToDate 2020 [acceso: 11/05/2020] Available in: https://www.uptodate.com/contents/nonselective-nsaids-overview-of-adverse-effects

Le Pham D, Lee JH, Park HS. Aspirin-exacerbated respiratory disease: an update. Curr Opin Pulm med 2017 [acceso: 11/05/2020]; 23(1):89-96(8) Available in: https://doi.org/10.1097/MCP.0000000000000328

Sung-dong K, Kyu-Sup Ch. Samter’s triad: state of the art. Clin Exp Otorhinolaryngol 2018 [acceso: 05/01/2020]; 11(2):71-80 Available in: https://doi.org/10.21053/ceo.2017.01606

Kowalski, ML, Agache I, Bavbek S, Bakirtas A, Blanca M, Bochenek G, et al. Diagnosis and management of NSAID‐Exacerbated Respiratory Disease (N‐ERD)-a EAACI position paper. Eur J Allergy Clin Inmunol 2018 [acceso: 09/03/2020]; 74(1):28-39 Available in: https://doi.org/10.1111/all.13599

Ledford DK., Lockey RF. Aspirin or Nonsteroidal Anti-inflammatory Drug–Exacerbated Chronic Rhinosinusitis. J Allergy Clin Immunol Prac 2016 [acceso: 19/02/2020]; 4(4):590-8 Available in: https://doi.org/10.1016/j.jaip.2016.04.011

Adappa ND, Ranasinghe VJ, Trope M, Brooks SG, Glicksman JT, Parasher AK et al. Outcomes after complete endoscopic sinus surgery and aspirin desensitization in aspirin-exacerbated respiratory disease. Int Forum Allergy Rhinol 2018 [acceso: 26/03/2020]; 8(1):49-53. Available in: https://doi.org/10.1002/alr.22036

Studer M.B. Roland LT, Ochsner MC, Cox D, DelGaudio JM, Wise SK, et al. Aspirin-Exacerbated Respiratory Disease With Allergic Fungal Rhinosinusitis: A Case Series of Overlapping Sinonasal Endotypes. Am J Rhinol Allergy 2020 [acceso: 14/02/2020] Available in: https://doi.org/10.1177/1945892420903587

Le Pham D, Lee JH, Park HS. Aspirin-exacerbated respiratory disease: An update.Curr Opin Pulm Med 2017 [acceso: 04/04/2020]; 23(1):89-96. Available in: https://doi.org/10.1097/MCP.0000000000000328

Woessner KM. Update on aspirin-exacerbated respiratory disease. Curr Allergy Asthma Rep 2017 [acceso: 29/01/2020]; 17(2) Available in: https://doi.org/10.1007/s11882-017-0673-6

Cahill KN, Johns CB, Cui J, Wichner P, Bates DV, Laidlaw TM, et al. Automated identification of an aspirin-exacerbated respiratory disease cohort. J Allergy Clin Immunol 2017 [acceso: 23/02/2020]; 139(3):819-25.e6 Available in: https://doi.org/10.1016/j.jaci.2016.05.048

Castillo Vizuete JA, Sastre J, del Cuvillo Bernal A, Picado C, Martínez Moragón E, Ignacio García JM et al. Rinitis, poliposis nasal y su relación con el asma. Arch Bronconeumol 2018 [acceso: 15/02/2020]; 55(3):146-55 Available in: https://doi.org/10.1016/j.arbres.2018.09.0019

Park H, Choi Y, Jung CG, Park HS. Potential biomarkers for NSAID-exacerbated respiratory disease. Mediat Inflam 2017 [acceso: 04/04/2020]; 2017: 8160148. Available in: https://doi.org/10.1155/2017/8160148

Lee JH, Jung CG, Park HS. An update on the management of aspirin-exacerbated respiratory disease. Expert J Resp Med 2018 [acceso: 13/01/2020]; 12(2):137-43 Available in: https://doi.org/10.1080/17476348.2018.1417843

Juri MC, fernández DS, Larrauri B, Malbrán E, Torre G, Malbrán A. Alergia a drogas. experiencia en 771 procedimientos. Medic 2017 [acceso: 20/03/2020]; 77(3):180-4. Disponible en: https://medicinabuenosaires.com/revistas/vol77-17/n3/180-184-Med77-1-6546-Juri.pdf

Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinop-hil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Resp Med 2016 [acceso: 14/02/2020]; 4(7):549-56 Available in: https://doi.org/10.1016/S2213-2600(16)30031-5

Simon RA, Cutlip D. Introduction of aspirin to patients with aspirin hypersensitivity requiring cardiovascular interventions. UpToDate 2018 [acceso: 28/03/2020] Available in: https://www.uptodate.com/contents/introduction-of-aspirin-to-patients-with-aspirin-hypersensitivity-requiring-cardiovascular-interventions

Xu JJ, Sowerby L, Rotenberg BW. Aspirin desensitization for aspirin-exacerbated respiratory disease (Samter's Triad): a systematic review of the literature. Int Forum Allergy Rhinol 2013 [acceso: 05/05/2020]; 3(11):915-20. Available in: https://doi.org/10.1002/alr.21202

Tajudeen B, Schwartz JS, Bosso JV. The role of aspirin desensitization in the management of aspirin-exacerbated respiratory disease. Curr Opin Otolaryngol H N Surg 2017 [acceso: 15/02/2020]; 25(1):30-4 Available in: https://doi.org/10.1097/moo.0000000000000331

Simon RA. Diagnostic challenge and desensitization protocols for NSAID reactions. UpToDate 2019 [acceso: 15/05/2020] Available in: https://www.uptodate.com/contents/diagnostic-challenge-and-desensitization-protocols-for-nsaid-reactions

Blais CM, Davis BE, Cockcroft DW. Duration of bronchoprotection of the long-acting muscarinic antagonists tiotropium & glycopyrronium against methacholine-induced bronchoconstriction in mild asthmatics. Resp med 2016 [acceso: 05/02/2020]; 118:96-101. Available in: https://doi.org/10.1016/j.rmed.2016.07.017

Williams AN. Diagnostic Evaluation in Aspirin-Exacerbated Respiratory Disease. Immunol Allergy Clin North Am 2016 [acceso: 12/01/2020]; 36(4):657-68. Available in: https://doi.org/10.1016/j.iac.2016.06.003

Simon RA. Aspirin-exacerbated respiratory disease: NSAID challenge and desensitization. UpToDate 2020 [acceso: 13/03/2020] Available in: https://www.uptodate.com/contents/aspirin-exacerbated-respiratory-disease-nsaid-challenge-and-desensitization

Walters KM, Waldram JD, Woessner KM, White AA. Long-term clinical outcomes of aspirin desensitization with continuous daily aspirin therapy in aspirin-exacerbated respiratory disease. Am J Rhinol Allergy 2018 [acceso: 15/05/2020]; 32: 280-6. Available in: https://doi.org/10.1177/1945892418770260

Enlaces refback

  • No hay ningún enlace refback.


Bookmark and Share


Licencia de Creative Commons
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional.